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Functional Residual Capacity 
Total Lung Capacity 
Forced Vital Capacity 
Forced Expiratory Volume in 1 second 
Residual Volume 
Single breath Carbon Monoxide Transfer Factor 
Transfer coeffient 
Partial pressure of oxygen 
Partial pressure of CO2 
Partial pressure of Oxygen in arterial blood 
Partial pressure of Carbon Dioxide in arterial 
blood 
Alveolar arterial oxygen gradient 
Ventilation Perfusion ratio 
Oxygen uptake 
Carbon dioxide production 
Shunt fraction 
Dead space to tidal volume ratio 
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3 SUMMARY 
There have been numerous reports of cardiovascular and 
pulmonary abnormalities in patients with cirrhosis and portal 
hypertension. The role of portal hypertension in the 
pathogenesis of pulmonary abnormalities in patients with liver 
disease has not been defined. The present study was therefore 
undertaken to clarify this. 
Pulmonary function, including exercise testing, was evaluated 
in two groups of patients, 11 with portal hypertension due to 
cirrhosis and 10 with extrahepatic portal vein thrombosis and 
normal liver histology. Carbon monoxide gas transfer (TLCOsb) 
was less than 75% of predicted values in four patients from each 
group. One patient from each group had clinical and catheter 
confirmed evidence of pulmonary hypertension. Abnormal 
cardiorespiratory responses to exercise occurred in three 
patients in the extrahepatic group. Two had associated low 
TLCOsb and one developed arterial desaturation on exercise. A 
similar pattern was seen in three patients with cirrhosis. All 
had low TLCOsb and one developed arterial desaturation during 
exercise. In the cirrhotic group however three additional 
patients showed reduction in Pa02 unassociated with elevated 
heart rate response on exercise. There was no significant 
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correlation with the presence of autoimmune antibodies which 
appear to be a secondary phenomenon. 
Our results suggest that pulmonary hypertension is linked to 
the presence of portal hypertension. Reduction in arterial P02, 
appears to occur only in patients with liver disease, presumably 
on the basis of intrapulmonary shunting. 
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4 INTRODUCTION - Pulmonary Abnormalities in Liver Disease 
In 1884 Fluchliger described a cirrhotic patient with cyanosis 
and clubbing and no apparent cardiovascular or respiratory 
disease. Since this original description certain pulmonary 
abnormalities have been well documented and in addition certain 
cardiovascular effects have been observed including tachycardia, 
increased aortic blood flow, widened pulse pressure, expanded 
blood volume, reduced vascular resistance and shortened 
circulation time {1). The pulmonary abnormalities are: 
4.1 Arterial hypoxaemia 
Arterial desaturation was initially thought to be due to a shift 
to the right of the oxygen dissociation curve as demonstrated by 
Snell and Keys (1) in vitro. It appears however, in vivo, that 
while there may some minor shift of the curve it contributes 
little, if at all, to the observed desaturation. Anaemia has 
also been suggested to contribute but abnormalities of reaction 
rate between oxygen and haemoglobin, and the functional 
impairment of the erythrocyte have so far not been adequately 
studied. In addition while these may explain a degree of 
desaturation they do not readily explain a reduction in Pa02. 
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Restriction of chest wall movement and lung volumes by tense 
ascites cannot be the explanation as desaturation is observed in 
the absence of ascites. Ruff et al (4) using 133Xe demonstrated 
increased closing volumes in 10 seated cirrhotic patients and in 
8 of these it was greater than the FRC. They concluded that the 
V/Q ratio of the dependent lung zones may be very low primarily 
as a result of decreased ventilation due to airway closure. They 
postulated this may be due to mechanical compression of small 
airways by dilated blood vessels and/or interstitial pulmonary 
oedema. Other studies have shown normal closing volumes and 
Schomerus (13) demonstrated no inequality as judged by nitrogen 
washout. In addition over half the patients who were studied 
were smokers. In his study of cirrhotic patients Schomerus (13) 
found reduced diffusing capacity to be an important contributing 
factor to the desaturation. While low carbon monoxide and oxygen 
diffusion have been shown to occur in cirrhotic patients the 
reasons for this are not clear. 
of fibrosing alveolitis associated 
the deg~ee of alveolar membrane 
Apart from the occasional case 
with chronic active hepatitis 
damage is not sufficient to 
account for the measured abnormalities and regional ventilation 
abnormalities have not been consistently demonstrated(l3,14). 
While true shunting can occur through portopulmonary channels, 
intrapulmonary vascular malformations or 
the pleural surfaces the magnitude 
through spider naevi on 
of anatomic shunts 
demonstrated has not correlated with the degree of desaturation 
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observed(lS,16). It has also been pointed out that because of 
the high oxygen tension in portal blood, it would require massive 
porto-pulmonary shunting to affect arterial saturation 
significantly. 
The most attractive explanation follows from the demonstration 
of intrapulmonary shunting by various techniques including 
systemic scanning following the injection of radioactive 
macroaggregated albumin.(16,17,18) Dilated gas exchanging vessels 
are thought to result in reduced transit time and increased 
diffusion distance to central erythrocytes. In this way the end 
pulmonary capillary blood is prevented from reaching equilibrium 
with alveolar oxygen tension. The degree of desaturation has 
been shown to have some correlation with liver function in the 
individual patient and it has been suggested that this is a 
hepatopulmonary syndrome analagous to the well known hepatorenal 
syndrome(l9). Why the intrapulmonary vascular channels should be 
dilated is uncertain. It may result from an endogenous 
vasoactive product which is normally metabolised by the liver, 
although the nature of this substance is unknown. Daoud (20) has 
demonstrated loss of pulmonary vasoconstrictor response in 
cirrhotic patients but Naejie (21) who was unable to confirm this 
observation speculates that Daoud's patients may have had 
endotoxaemia. 
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4.2 Pulmonary Hypertension 
Mantz and Craig noted the occurrence of pulmonary hypertension 
and portal hypertension thirty years ago and this observation has 
been subsequently confirmed. Lebrec et al (3) reported 9 
patients with pulmonary hypertension complicating portal 
hypertension. The cause of the portal hypertension was cirrhosis 
in 7 patients, nodular regenerative hyperplasia of the liver in 1 
and portal vein obstruction in 1. They postulated that pulmonary 
hypertension might result from the effect of a vasoconstrictive 
agent or substance toxic to the pulmonary arterial walls, which 
is produced in the splanchnic territory and normally destroyed by 
the liver. 
A recent large study by Mcdonnel et al (4) would appear to 
exclude a coincidental association. They found a prevalence of 
primary pulmonary hypertension in an unselected series of 17901 
autopsies of 0.13% in all patients but 0.73% among patients with 
cirrhosis (p<0.001). A clinical series of 249 patients with 
biopsy proven cirrhosis showed a prevalence of 0.61% which is 
also significant (p<0.001) compared to the autopsy series. 
However, the description of pulmonary hypertension in patients 
with portal vein thrombosis and normal liver histology (5) 
suggests that this pulmonary hypertension may be due to impeded 
portal venous blood flow and not to hepatic dysfunction. 
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4.3 Respiratory Alkalosis 
Hyperventilation and respiratory alkalosis are frequently 
observed in cirrhotic patients, particularly those who are 
encephalopathic. The exact mechanism of this disorder is 
unknown. The decrease in arterial oxygen saturation observed is 
insufficient to account for the hyperventilation. Other possible 
mechanisms have been suggested. Progesterone has been shown to 
be a respiratory stimulant and is thought to be responsible for 
the hyperventilation of pregnancy. Progesterone is broken down 
by the liver and increased levels of this hormone have been 
postulated to be responsible for hyperventilation in cirrhotic 
patients. 
Ammonia has also been implicated. Levels of ammonia have not 
been consistently correlated with the degree of 
hyperventilation. This has been ascribed to secondary effects of 
hydrogen ion concentration on the dissociation of ammonium. NH4 
is poorly diffusable but in the presence of extracellular 
alkalosis forms ammonia (NH3) which rapidly enters cells and may 
stimulate ventilation out of proportion to its extracellular 
concentration. Karetzky (24) et al measured the ventilatory 
response to CO2 in 7 subjects and found it to be significantly 
augmented in the range 30-40 mmHg, suggesting diminished 
tolerance to CO2. This they suggest is compatible with a state of 
intracellular acidosis consequent on a low energy state of the 
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cells with an inability to actively extrude hydrogen ions. 
Mulhausen et al (25) investigated the acid base status of 91 
patients with cirrhosis. They found that although respiratory 
alkalosis was frequently present, this was not a pathognomonic 
disturbance. All varieties of acid base disturbance were 
observed but the common denominator was the reduction in the 
partial pressure of CO2. They also found that in each instance of 
reduced bicarbonate concentration, most of the deficit could be 
accounted for by elevated levels of lactate and pyruvate. The pH 
depended on the severity of the existing bicarbonate deficit in 
the presence of reduced pC02. No correlation was found between 
acid base and mental status. 
4.4 Pulmonary Oedema 
The incidence 
hepatic failure 
al ( 26) .found 37 
of pulmonary oedema in patients with fulminant 
is high. In a series of 100 patients Trewby et 
with clinical and radiological evidence of 
pulmonary oedema. These patients had no clinical evidence of 
left heart failure and the pulmonary capillary wedge pressure 
measured in 12 of them was normal. There was no evidence to 
incriminate renal failure, endotoxaemia or hypoalbuminaemia. 
There was however a significantly high incidence of pulmonary 
oedema in patients with cerebral oedema suggesting either a 
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central origin for the pulmonary oedema or common factors 
predisposing to oedema in both sites. 
4.5 Chest Radiograph Abnormalities 
The presence of chest radiographic abnormalities in cirrhotics 
not explained by infection, fluid overload etc has been 
investigated by Stanley and Woodgate (21). The shadows are 
usually nodular, occurring at the bases, and are felt to be due 
to dilated intrapulmonary vessels. Radiographic shadowing . 
appears to vary with the severity of liver dysfunction. 
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4.6 Aim of the study 
While, as noted above, there have been reports of pulmonary 
hypertension in patients with extrahepatic portal hypertension, 
the arterial oxygen desaturation does not appear to occur in this 
group. This however has not previously been systematically 
studied. The aim of this study was therefore to clarify the 
relationship between these two pulmonary abnormalities and liver 
disease by studying lung function and exercise responses in two 
groups of patients; patients with extrahepatic portal 
hypertension with normal liver function and patients with portal 
hypertension due to cirrhosis. 
Reports of pulmonary hypertension occurring in patients with 
chronic active hepatitis have suggested that this may be a 
manifestation of an auto-immune process. Measurements were 
therefore made of autoimmune markers to try and establish if 
these reflected paraphenomena rather than being of aetiological 
importance. 
5 PATIENTS 
The study had the approval of the ethics committee of the 
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University of Cape Town and Groote Schuur Hospital and all 
patients gave informed consent. All patients with well 
documented portal hypertension who were contactable, and able and 
prepared to participate were considered for the study. The 
majority of patients had initially presented with variceal 
bleeding and had had various radiological investigations 
including catheter studies and liver biopsies performed by their 
own physicians prior to their admission into this study. 
Patients were excluded from analysis if they were unable to 
perform exercise tests or had evidence of significant unrelated 
cardiovascular or pulmonary disease. Those with liver disease 
were studied when clinically stable and none of the patients were 
encephalopathic. Patients undergoing variceal sclerotherapy were 
not studied within a week of the procedure. 
6 METHODS 
Symptoms were recorded using the American Thoracic Society 
Respiratory Questionnaire,(6) modified to include data relating 
to liver disease and portal hypertension. Chest radiographs and 
electrocardiographs were obtained for each patient. 
Lung functions included full lung volumes, flow volume loop, 
single breath diffusing capacity for carbon monoxide, closing 
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volumes and measurement of maximal inspiratory and expiratory 
pressures. Schonbergs(7) predicted values were used for flow 
volume and spirometric data, Grimby's (8) for lung volumes and 
Buist's (9) for closing volumes. Normal values for TLCOsb were 
taken from Cotes (10) and those for maximum inspiratory and 
expiratory pressures from Wilson.(11) 
Liver function was 
index, serum albumin and 
assessed by 
hepatic 
measurement of prothrombin 
enzymes. Liver histology was 
available for each patient. In addition Rheumatoid factor, 
anti-DNA antibodies, antinuclear factor, antismooth muscle 
antibodies, antimitochondrial antibodies and circulating immune 
complexes were determined in each case. 
Exercise testing was performed using the Jones protocol with a 
cycle ergometer (12). End tidal PC02, inspired minute 
ventilation, heart rate, blood pressure, and arterial oxygen 
saturation (ear oximetry) were measured during progressive 
testing to exhaustion (stage 1). A 12 lead ECG was run and FEVl 
and FVC were measured before and after exercise. 
Steady state measurements were taken at rest and at 
approximately 60% of maximum workload as determined by the stage 
1 test. Blood gasses were measured by means of arterialised 
capillary earlobe blood and cardiac output estimated by the CO2 
Fick method following a rebreathing manouevre. Measurements were 
made of end-tidal fractional CO2 and mixed expired CO2 and 02 
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fractions. Standard equations were used to calculate oxygen 
consumption, carbon dioxide production, alveolar arterial oxygen 
tension gradients, shunt fraction and dead space to tidal volume 
ratio (12). 
In addition Swan Ganz right heart catheterisation was performed 






function was measured with 
The computerised system was 
seal spirometer interfaced 
computerised and 
a Morgan Model 




microcomputer. The Morgan Transfer test apparatus was used for 
single breath TLCOsb and results were corrected for haemoglobin. 
Closing volumes were measured with a single breath nitrogen 
washout technique using a HP47302A Nitrogen analyser and the dry 
rolling seal spirometer. 
used for Flow Volume loops 
A Medscience 570 Wedge Spirometer was 
and lung volume subdivisions were 
measured by Helium dilution with a Godart Expirograph. A Siemens 
Elema electrically braked cycle ergometer RE820 was used for the 
exercise tests. Ventilation was measured with a Parkinson Cowan 
dry gas meter; gas analysis was by Applied Electrochemistry S3A 
- 18 -
Oxygen analyser and a Morgan 901 Mk2 CO2 analyser; and ear oxygen 
saturation by Hewlett Packard 4201A ear oximeter all linked to a 
Siemens Elema Mingograf 82 chart recorder. Analyses were 
calibrated with reference gases analysed by the Lloyd-Haldane 
technique. Blood gases were measured on a Radiometer ABL3 blood 
gas analyser. 
8 RESULTS 
8.1 Clinical Features. 
Patients with cirrhosis were generally older and smoked more 
than those with portal vein thrombosis. The male to female ratio 
was also different, there being more males in the liver disease 
group. (Table 1.) None Df the subjects had symptoms of asthma or 
atopy and none reported daily sputum production. Nine subjects 
felt that they were more dyspnoeic on effort than other people of 
their age although only two described effort limitation class 2 
NYHA or greater. Both of these subjects had clinical, 
radiological and electrocardiographic evidence of pulmonary 
hypertension. One had portal vein thrombosis (patient 9) and the 
other chronic active hepatitis with cirrhosis (patient 21). None 
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of the patients were cyanosed at rest and only 1 had finger 
clubbing (patient 20) 
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Patient Pack 
No Age Sex Diagnosis Splenectomy Yrs Last smoked 
1 26 Female Portal Vein Thrombosis No 0 NA 
2 17 Female Portal Vein Thrombosis No 0 NA 
3 19 Female Portal Vein Thrombosis No 0 NA 
4 17 Male Portal Vein Thrombosis No 0 NA 
5 32 Male Portal Vein Thrombosis No 3 7 Years ago 
6 25 Female Portal Vein Thrombosis Yes 0 NA 
7 18 Female Portal Vein Thrombosis No 0 NA 
8 20 Male Portal Vein Thrombosis No 0 NA 
9* 31 Female Portal Vein Thrombosis No 0 NA 




No Age Sex Diagnosis Splenectomy Yrs Last smoked 
11 33 Female Macronodular Cirrhosis No 0 NA 
12 49 Male Alcoholic Cirrhosis No 50 14 yrs.ago 
13 27 Male Scleros.Chol Cirrhosis No 0 NA 
14 37 Male Alcoholic Cirrhosis No 20 Current 
15 44 Female Chronic Active Hepatitis No 0 NA 
16 22 Male Post Hep. Cirrhosis No 0 NA 
17 22 Male Post Hep. Cirrhosis No 0 NA 
18 37 Male Alcoholic Cirrhosis No 20 Current 
19 43 Female Alcoholic Cirrhosis No 12 Current 
20 49 Male Alcoholic Cirrhosis No 30 Current 
21* 37 Female Chronic Active Hepatitis No 25 Current 
Mean 36.7 
M:F 7:4 
Table 1 Clinical data 
* clinical and catheter confirmed pulmonary hypertension 
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8.2 Chest Radiographs. 
These were evaluated for evidence of pulmonary hypertension and 
parenchymal abnormalities. Only the two patients with clinical 
pulmonary hypertension had radiographs clearly supporting this 
diagnosis. Other unrelated abnormalities noted included 
calcified foci in keeping with healed (probably tuberculous) 
granulomas, elevated hemi-diaphragm in 1 patient and minor upper 
lobe shadows suggestive of previous tuberculosis in 1 patient. 
8.3 Electrocardiogram 
These were normal in 14 patients. Patients 17 & 18 had right 
. 
bundle branch block, patient 8 ectopic atrial pacemaker with 
intraventricular conduction delay, patient 9 severe right 
ventricular hypertrophy and patient 21 right axis deviation. 
patients 12 & 14 had non specific anterior T wave changes. 
8.4 Ventilatory function. 
The lung volumes and flow rates expressed as a percentage of 
predicted were not significantly different in the two groups and 
all were within the normal range. (table 2.) There was no 
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significant abnormality of Maximal inspiratory or Expiratory 
pressures or closing volumes as measured by Nitrogen washout. 
The only significant abnormality of lung function was reduction 
in the TLCOsb. This was equal to or less than 75% predicted 
(after correction for haemoglobin) in 4 patients with portal vein 
thrombosis (3,4,5,9) and in 5 patients with liver disease. 
(11,14 19,20,21). 
8.5 Serology and biochemistry. 
Liver function was well preserved in both groups. Of the 
cirrhotic patients only one was hypoalbuminaemic (patient 17) and 
2 had low prothrombin indices. Minor elevations of circulating 
immune complexes and rheumatoid factor were noted in some 
patients as can be seen in table 3. These are felt to be 
secondary phenomena as none of the patients had other evidence of 
collagen vascular disease. 
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Patient 
No FVC FEVl FEVl/FVC TLC TLCO 
1 98 92 79 101 88 
2 110 96 78 98 98 
3 102 100 84 111 64 
4 84 82 88 91 74 
5 97 85 70 101 65 
6 115 112 83 134 92 
7 93 88 83 103 100 
8 123 115 78 112 103 
9 105 112 86 120 56 
10 113 118 84 106 79 
Mean 104 100 81. 3 107.7 81. 9 
+- SD 11. 59 13.37 5.18 12.29 16.7 
Patient 
No FVC FEVl FEVl/FVC TLC TLCO 
11 87 90 86 102 75 
12 110 103 72 106 76 
13 100 82 66 94 77 
14 112 116 78 120 64 
15 118 125 84 107 105 
16 96 90 80 93 78 
17 127 120 84 116 94 
18 93 104 89 98 128 
19 90 96 86 108 69 
20 105 100 81 92 71 
21 105 102 78 100 57 
Mean 103.9 102 80.3 103.2 81. 2 
+- SD 12.3 13.3 6.7 9.1 20.3 
Table 2 . Lung function tests expressed as a% of predicted values. 
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Patient no PI Albumin Bilirubin Latex Anti DNA Irnm.Compl. 
1 75 38 7 0 2 5 
2 75 46 15 0 8 3 
3 100 42 19 0 10 3 
4 86 39 20 0 6 3 
5 74 43 10 0 0 0 
6 76 41 5 0 3 6 
7 74 35 18 0 8 11 
8 77 44 41 0 6 9 
9 90 29 4 160 0 38 
10 86 47 10 0 0 0 
Mean 80.1 40.2 15 4.7 7.8 
+-SD 9.9 5.2 10.5 3.8 10.6 
Patient no PI Albumin Bilirubin Latex Anti DNA Irnm.Compl. 
11 78 38 21 0 9 8 
12 80 44 24 0 0 3 
13 82 39 17 0 24 5 
14 68 39 14 0 4 6 
15 90 41 12 0 12 18 
16 60 42 15 0 8 8 
17 77 34 19 0 3 0 
18 71 39 44 640 4 4 
19 77 40 11 0 1 0 
20 75 38 14 0 0 0 
21 88 43 34 0 0 0 
Mean 76.8 39.9 20.4 5.6 4.8 
+-SD 9.0 2.8 10.7 7.5 5.4 
Normal 100 >35 <17 <7 <5 
Table 3 Biochemical and serological data. 
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8.6 Exercise Tests 
Tables 4 & 5 
8.6.1 Extrahepatic group 
Progressive exercise tests were considered submaximal in 3 of the 
patients. The most striking feature was the markedly exaggerated 
heart rate response observed in 3 patients (2,3, and 9). These three 
patients also had marked hyperventilation with arterial PaC02 below 
35mm/Hg at rest and on exercise. Two also had a low TLCOsb (subjects 
3 and 9). Representative cardiac and ventilation response graphs are 
shown in figure la+ b. One patient (patient 9) had clinical evidence 
of pulmonary hypertension. This was confirmed with pulmonary artery 
catheterisation which showed pulmonary artery pressures approaching 
systemic values on exercise. Patients 3 & 9 showed a rise in PaC02 
and dead space/tidal volume ratio on exercise. The tachycardia and 
limited stroke volume in the three subjects was confirmed on steady 
state testing. Two other patients (4,5) had moderately elevated heart 
rate responses which were associated with alveolar hyperventilation 
and development of mild metabolic . 
8:6.2 Liver disease group 
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Progressive exercise tests were considered submaximal in 6 
patients. 
patients 
Markedly elevated heart rate responses were seen in three 
(11,19 & 21). All three had low TLCOsb. Subject 21 had 
clinical pulmonary hypertension and pulmonary artery catheterisation 
confirmed severe pulmonary hypertension. Three other subjects (14,18 
and 20) developed widened alveolar arterial oxygen tension gradients 
and a fall in arterial Pa02 on exercise unassociated with elevated HR 
response (fig le). In subject 20 this was associated with the 
development of metabolic acidosis. 
TLCOsb. 
Subjects 14 & 20 had reduced 
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Patient %Fred % H.R V.E B.P Break 
No Age TLCO Work Max Res Res Res Away 
1 26 88 55 No Normal High Normal No 
2 17 98 36 No High High Normal No 
3 21 64 60 Yes High High Low Yes 
4 17 74 90 Yes Sl.Hi Normal Normal Yes 
5 32 65 90 Yes Sl.Hi High Normal Yes 
6 25 92 87 Yes Normal Normal Normal Yes 
7 18 100 60 No Normal Normal Normal No 
8 20 103 78 Yes Normal Chaotic Normal Yes 
9 31 56 43 Yes High High Low Yes 
10 24 79 81 Yes Normal Normal Normal No 
Patient %Fred % H.R V.E B.P Break 
No Age TLCO Work Max Res Res Res Away 
11 33 75 53 Yes High High Normal Yes 
12 49 76 80 Yes Sl.Hi Normal Normal Yes 
13 27 77 60 No Normal High Normal Yes 
14 14 64 65 Yes Normal High Normal Yes 
15 44 105 70 Yes Sl.Hi High Normal No 
16 22 78 42 No Normal Normal Normal Yes 
17 22 94 50 No Normal Normal Normal No 
18 37 128 44 No Normal High Normal Yes 
19 43 69 40 No High Normal Normal No 
20 49 71 95 Yes Low Normal Normal No 
21 37 57 60 No High High Normal Yes 
Table 4. Single breath Carbon Monoxide gas transfer and Stage 1 Exercise 
test results. 
%Fred TLCO =%of predicted TLCO 
% Work =%of predicted maximum workload the patient completed. 
H.R. Res = Heart Rate response 
V.E Res ~ Ventilatory response 
B.P Res = Blood Pressure response 
Break away= Presence of terminal breakaway response of ventilation 
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Workload V02 R PaCo2 Pa02 A-a VD/VT HR pH 
ml.kg mmHg mmHg 
1 0 4.40 .78 22 116 5 34 64 7.58 
300 17.30 .93 34 110 2 20 125 7.38 
2 0 4.80 .75 31 105 3 21 96 7.42 
200 16.10 .94 29 105 13 15 160 7.38 
3 0 5.20 .66 30 91 17 27 88 7.42 
300 21. 60 .83 34 85 26 29 170 7.39 
4 0 5.70 .94 39 90 17 28 92 7.39 
400 23.20 .91 32 87 26 10 170 7.35 
5 0 5.20 .98 34 107 8 28 75 7.44 
600 26.10 .87 27 84 36 8 156 7.36 
6 0 6.40 .78 37 97 6 31 90 7.41 
400 28.80 1.02 35 99 15 15 160 7.38 
7 0 4.30 .72 36 90 13 26 75 7.39 
400 22.80 .91 32 101 15 9 143 7.39 
8 0 4.60 1. 21 28 111 14 33 94 7.53 
700 27.00 1. 08 32 102 17 7 140 7.42 
9 * 0 4.50 .76 28 91 23 20 86 7.43 
100 16.90 .87 32 77 37 32 150 7.39 
10 0 5.00 .87 26 101 20 23 88 7.54 
500 28.60 .75 34 0 0 10 120 7.41 
Mean a) 5.0 .84 31.1 99.9 12.6 27.1 84.8 7.45 
+-SD . 6 .16 5.3 9.6 6.8 4.7 10.1 
b) 22.8 .91 32.2 94.4 20.7 15.5 149.4 7.38 
4.8 2.4 11. 3 11. 4 8.8 17.3 
Table 5 Exercise data in patients with extrahepatic portal hypertension 
* Clinical pulmonary hypertension 
! 0 = unreliable data 
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Workload V02 R PaCo2 Pa02 A-a VD/VT HR pH 
ml.kg mmHg mmHg 
11 0 4.90 .76 33 95 13 31 87 7.42 
300 16.90 .98 28 104 16 14 170 7.34 
12 0 3.70 .73 33 90 14 30 92 7.42 
500 15.20 1. 09 38 90 22 18 147 7.38 
13 0 3.10 1.11 32 101 19 19 60 7.45 
450 16.30 1.19 31 110 13 5 125 7.39 
14 0 3.60 .80 30 73 40 33 78 7.43 
500 17.10 . 93 26 61 60 27 113 7.41 
15 0 3.90 .74 35 93 12 34 81 7.42 
300 17.30 .80 31 98 15 21 129 7.41 
16 0 5.60 .86 36 90 18 31 90 7.41 
300 15.00 .88 35 91 18 20 124 7.37 
17 0 4.30 .76 37 93 11 34 98 7.43 
250 18.80 .97 35 101 13 16 127 7.41 
18 0 4.60 .73 33 98 8 30 72 7.45 
350 10.80 1. 01 35 88 26 24 98 7.39 
19 0 3.20 .80 38 83 21 35 110 7.40 
150 14.50 .70 40 81 14 28 140 7.39 
20 0 5.70 .77 39 105 0 37 56 7.41 
450 24.60 .71 40 80 16 40 144 7.26 
21* 0 3.70 .70 34 83 20 33 86 7.45 
200 10.40 .84 30 76 38 25 113 7.46 
Mean a) 4.2 . 79 34.5 91.2 17.6 31. 5 82.7 7.42 
+-SD . 9 .11 2.7 9.0 8.9 4.6 15.8 
b) 16.0 .91 33.5 89 22.8 21. 6 130.0 7.38 
3.8 .15 4.7 14.1 14.3 8.9 19.6 
Table 5 Exercise data in patients with liver disease and portal 
hypertension 
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9 DISCUSSION 
Pulmonary abnormalities, including arterial hypoxaemia and an 
increased incidence of plexogenic pulmonary hypertension, are well 
documented features of chronic liver disease (1-3). Most reports have 
attributed the plexogenic pulmonary hypertension seen in patients with 
liver disease to cirrhosis (3,4). 
The current theories 
desaturation have been 
regarding 
discussed 
the pathogenesis of 
(see 3.1) The fall in 
arterial 
Pa02 on 
exercise in three of our cirrhotic patients with normal cardiovascular 
responses (14,18 & 20) could not be explained on the basis of 
independent lung disease. 
While it is true that a number of subjects in the liver disease 
group were smokers, the absence of sputum production, normal chest 
radiographs and the presence of normal lung volumes and flow rates 
excludes, we believe, smoking as a cause of the reduced TLCOsb or the 
desaturation. As noted (section 4), patients considered to have 
unrelated cardiovascular or pulmonary disease were excluded from the 
study. Of the four subjects with reduced carbon monoxide gas transfer 
(14,19,20 & 21) a fall in Pa02 was only evident on exercise in two (14 
& 20). The desaturation may be due to an endogenous vasoactive 
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product, the nature 
metabolised by the 
clinically well, 
of which is unknown, but which would normally be 
liver. Our patients with liver disease were 
not encephalopathic, and as evidenced by the 
prothrombin indices and albumin levels, had relatively good liver 
functions. This may well explain why we observed hypoxaemia on 
exercise in only a small number of patients. 
The absence of desaturation in all but one of the patients with 
extrahepatic portal hypertension (in whom this could be accounted for 
by her proven pulmonary hypertension) supports the concept that 
defective oxygenation is related to liver disease per se and not to 
portal hypertension. 
While the presence or absence of desaturation can easily be 
determined, it is more difficult to diagnose pulmonary hypertension 
without right heart catheterisation. In mild or early pulmonary 
hypertension the physiological abnormalities demonstrable by 
non-invasive means are non-specific. While acknowledging these 
limitations, the abnormal cardiovascular responses to exercise coupled 
with the low TLCOsb observed in the extrahepatic group strongly 
suggests pulmonary vascular disease. The tachycardia present in three 
patients was more marked than would be expected from unfitness alone 
and these patients were all young and active. These responses 
contrasted with a group of the cirrhotic patients who though older and 
more likely to have been physically unfit dropped their arterial Pa02 
while showing normal cardiovascular response to exercise. Two of the 
three patients with markedly abnormal heart rate responses also 
- 33 -
demonstrated a low TLCOsb. 
Reduced TLCOsb observed in four of our patients has not previously 
been described in patients with extrahepatic portal hypertension in 
the absence of pulmonary hypertension. 
Our study shows that abnormal cardiovascular responses to exercise 
are not uncommon and we suggest these may be related to abnormalities 
in the pulmonary vasculature. A transient rise in pulmonary pressures 
can occur during sclerotherapy which most of our patients received 
(22). However the two patients with severe pulmonary hypertension (9 & 
21) did not have sclerotherapy and long term evaluation of the effects 
of sclerotherapy on .the pulmonary vasculature is not available. 
Of interest is that in both patients with confirmed 
hypertension the liver disease or portal hypertension 
pulmonary 
had been 
diagnosed more than 15 years earlier. This was considerably longer 
than the other patients in the study and would again support the 
concept of a long standing insult to the pulmonary circulation as the 
cause of the pulmonary hypertension. 
Our study suggests that pulmonary hypertension may develop in 
response to portal hypertension, whether hepatic or extrahepatic in 
origin and that the pulmonary response relates to the duration of 
portal hypertension. Conversely hypoxaemia occurs predominantly in 
patients with impaired liver function and may only be evidenced on 
exercise in 
independent. 
some patients. These two 
Indeed the pathophysiology 
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effects appear to be 
is completely different, the 
one resulting in apparently reversible pulmonary artery vasodilatation 
and the other in progressive irreversible obliteration of the 
pulmonary vascular bed. 
One can only speculate on the basis of the available published 
reports and experimental data as to what determines the development of 
the vascular changes. The two abnormalities have not been described 
occurring together and they would appear conceptually to be mutually 
exclusive. This study supports the concept of longstanding portal 
hypertension being linked to the development of pulmonary 
hypertension. Arterial desaturation appears to occur only in the 
presence of liver dysfunction and seems to reflect dynamic vascular 
changes which can occur more acutely and show varying degrees of 
severity in the same patient. The patients selected by having 
developed obliterative vascular changes would be incapable of 
significant pulmonary vasodilatation. Conversely the patients with 
vasodilatation as a result of severe liver disease may either have 
their survival limited by the liver disease before they can develop 
pulmonary hypertension or possibly are protected by the 
vasodilatation. 
The pathogenesis of plexogenic pulmonary hypertension remains 
obscure (27). Its occurrence in the setting of portal hypertension is 
used as evidence that it results from endothelial injury. Similarl~, 
suprisingly little is known about the mechanisms of vascular control 
both in the pulmonary and systemic vasculature (28). Here again 
attention is presently focused on the role of the endothelial cell. 
- 35 -
The patients with portal hypertension with and without cirrhosis are 
therefore of considerable interest as they are unique as models for 
these diseases. We have tried to separate 
our findings lend support to the proposed 
and pulmonary hypertension. 
- 36 -
the two groups and believe 
mechanism of desaturation 
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11 APPENDIX 1 Detailed lung function results 
Study Age Sex FVC FVC FEVl FEVl FEVl/ 
no Predicted Predicted FVC 
1 26 Female 3220 3270 2570 2790 79% 
2 17 Female 3250 2950 2550 2640 78% 
3 19 Female 2560 2490 2160 2150 84% 
4 17 Male 2820 3340 2490 3020 88% 
5 32 Male 4710 4820 3340 3890 70% 
6 25 Female 3380 2920 2800 2480 83% 
7 18 Female 3170 3390 2640 2980 83% 
8 20 Male - 5100 4130 4000 3470 78% 
9 31 Female 2350 2230 2030 1810 86% 
10 24 Male 4600 4050 3900 3290 84% 
11 33 Female 2830 3230 2420 2660 86% 
12 49 Male 5450 4910 3950 3830 72% 
13 27 Male 5250 5200 3450 4170 66% 
14 37 Male 5320 4710 4170 3590 78% 
15 44 Female 3900 3300 3300 2640 84% 
16 22 Male 3720 3860 2990 3320 80% 
17 22 Male 4400 3450 3700 3070 84% 
18 37 Male 5450 5840 4850 4640 89% 
19 43 Female 2650 2930 2300 2390 86% 
20 49 Male 3700 3910 3000 3000 81% 
21 37 Female 3860 3650 3020 2950 78% 
Volumes e~pressed in ml. 
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Detailed lung function - continued 
Study TLC TLC RV RV RV/ FRC FRC 
No Predicted Predicted TLC Predicted 
1 4270 4190 1250 930 29 2080 1900 
2 3810 3880 770 930 20 1800 1820 
3 3410 3050 930 560 27 1360 1350 
4 3940 4290 1130 1030 28 2080 2020 
5 6560 6450 2040 1630 31 3500 3260 
6 4870 3620 1000 700 21 2110 1650 
7 4440 4270 1200 880 27 2260 1850 
8 5890 5250 985 1120 17 2510 2540 
9 3400 2830 1080 600 31 1860 1320 
10 5580 5240 1170 1190 21 2120 2580 
11 4350 4230 143 990 33 2410 1940 
12 7040 6600 1980 1690 28 3100 3240 
13 6285 6640 1470 1440 23 3290 3190 
14 7380 6100 1680 1390 23 3190 2930 
15 4970 4610 1210 1310 24 2530 2190 
16 4640 4940 910 1080 19 2100 2410 
17 5210 4480 990 1030 19 2590 2230 
18 7280 7370 2110 1530 29 3880 3410 
19 4270 3920 1650 990 39 2270 1830 
20 5205 5640 1860 1730 36 3680 3020 
21 5030 5050 1170 1400 23 2910 3650 
Volumes in ml 
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Detailed lung function - continued 
Study TLCO* TLCO TLCO KCO KCO 
No Predicted Corrected Predicted 
l 17.13 26.79 23.63 4.24 5.65 
2 18.80 20.00 19.74 5.20 6.00 
3 15.37 25.69 16.59 5.04 5.75 
4 21. 51 29.02 21. 51 6.20 5.70 
5 21. ~7 34.48 22.75 3.38 5.33 
6 21. 00 24.90 23.10 5.30 5.70 
7 22.35 23.00 23.02 5.66 5.80 
8 33.14 32.20 33.47 5.8Q 5.80 
9 10.90 24.20 13.62 3.30 5.50 
10 25.00 29.70 23.75 4.60 5.60 
11 18.50 25.20 19.05 5.00 5.50 
12 27.00 33.80 25.92 3.90 4.70 
13 26.00 35.80 27.82 5.00 5.50 
14 17.90 31. 00 20.04 2.62 5.10 
15 26.00 24.90 26.26 5.15 5.30 
16 24.70 34.50 27.17 5.10 5.70 
17 19.67 23.00 21. 83 4.02 5.70 
18 34.90 I 28. 00 35.94 4.90 5.10 
19 15.00 22.80 15.75 5.00 5.30 
20 18.14 24.70 17.77 3.80 4.70 
21 15.60 27.00 15.60 3.37 5.40 
* ml/min/mmHg 
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FEV1: 2530 Pll 













-· '. -· 
M.LOAO HEART VEHT. RESP. 
kpPt/PI RATE L/PI RATE 
0 · 64 17 30 
100 89 19 28 
200 99 35 60 
300 111 35 55 
400 123 40 51 
500 135 46 38 
M.LOAD kpr,i'l'I REST 300 0 
HEART RATE ·· 64 125 0 
VI 1 /1"1 17 32 0 
Vt Pl 1 572 1062 0 
RESP.RATE 30 30 0 
V02 1"11 /r, 226 883 0 
V02 Pll/kg/M 4.4 17.3 0.0 
IJC02 1'11 /M 175 822 0 
R 0.78 0.93 0.00 
PEC02 MM 9 22 0 
PETC02 l'IM 17 24 0 
PVC02 "'M 34 51 0 
FVC: ·3959 ,.1 Rci-tio: 82 ~ 











Vt SC102 PetC02 BP BP 
1'11 % ""'Hg S!:lst. Dias. 
~72 97 17 100 70 
680 9? 23 
579 97 19 110 70 
638 97 23 
783 97 25 120 70 
1202 96 26 
W.LOAD kpPll'M REST 300 0 
Pa.CO2 ,.,, 22 34 0 
Vd/Ut % 34 20 0 
VA 1 /pi 11 26 0 
Pa.02 PIP! 116 110 0 
Sa.02 ~ 99 98 0 
PA02 .... 121 113 0 
A-<1002 ""' 5 2 0 QS/QT % 0 0 0 
QT 1 /1"1 2.6 10.1 0.0 
STR.IJOL "1 41 81 0 PH 7.58 7.38 0.00 
LACTATE 1'11"1/l 0.0 0.0 0.0 
Patient 1 
SPIRONETRY: 
Pre-exercise: FEV1: 2480 "' 
Lowest post-: FEU1: 2450 "1 


















W.LOAD HEART VENT. RESP. 
kptVl'I RATE L/M RATE 
0 96 11 17 
100 130 23 27 
200 150 30 32 
300 170 42 40 
400 175 S0 48 
W.LOAD kp"/" REST 200 0 
HEART RATE 96 160 0 
VI 1/ .. 11 37 0 
Vt "1 619 958 0 RESP.RATE 17 39 0 
V02 "'/" 274 923 0 IJ02 .. l/kg/ .. 4.8 16.1 0.0 
VC02 .. 1.., .. 205 870 0 
R 0.75 0.94 0.00 
PEC02 ,.,. 17 20 0 
PETC02 .... 32 25 0 
PIJC02 ""' 42 52 0 
- - -· 
FVC: 2940 1'11 


















. . . . . . . . . . . . . . . . . . . . . . . . 
0.__.,_1 ....,.2~3~4~5~6~?~8----=-9~10,,.-..,1~2 
W.LOAD(x100)kp"/"in 
Sa02 PetC02 BP BP 
~ Ml'!Hg Syst. Dias. 
96 32 130 75 
95 32 150 90 
96 29 
96 26 150 90 
96 2S 
- ----
' W.LOAD kpft/f1 REST 200 0 / 
I 
PaC02 ..... 31 29 :1 Vd/Vt ~ 21 15 
VA 1 /f'I 8 32 0 
Pci02 "" 105 105 0 SC102 ~ 98 98 0 
PA02 ,.,, 109 117 0 
A-ciD02 ""' 3 13 0 QS/QT % 0 1 0 
QT 1 ..,,. 3.6 8.1 0.0 
STR.IJOL "1 37 50 0 
PH 7.42 7.38 0.00 
LACTATE ""';, 1 0.0 0.0 0.0 
Patient 2 
PREDICTED VALUES: FEVt: 2129 ftl FVC: 2470 ~1 




FEV l : 1910 "1 
FEVl: 1969 Pll 
299 ................. •.• .. 
189 
169 
140 .. ··· 
. . . . 
.. ····· 
. . . .. . 
FVC: 2359 "' Ra. tio: 81 










120 . . . . L/"' 
• • • • • • • • • • • ••••••
••• lit : t • 
190 
80 
. . . 
~e .__~~l!!--4~.-r-~it--~~~ 2 
M.LOAO(x109)kp~l~in 
M.LOAD HEART VENT. RESP. 
kp,v,. RATE L/r, RATE 
9 88 11 . 20 
100 110 11 0 
200 135 22 27 
300 150 40 42 
400 160 48 42 
500 180 55 48 
600 185 64 ~0 
M. LOAD kpA,.'M REST 300 0 
HEART RATE . 88 170 0 
VI 1 /1'1 11 41 0 
Vt P11 554 1110 0 
RESP.RATE 20 37 0 
V02 "'1 i'l"I 263 1102 0 
V02 Pll /k9 . .t'J11 5.2 21. 6 0.0 
VC02 Ml/M 173 915 0 
R 0.66 0.83 0.00 
PEC02 1111"! 14 · 19 0 
PETC02 MM 28 21 : 0 



















Sa02 P~tC02 BP BP 
~ rn11H9 S~st. Oia.s. ' i 
94 28 110 78 
95 0 
92 24 130 70 
92 20 
91 22 139 70 
91 22 
91 20 130 79 
W.LOAD kpM/1"1 REST 300 0 
Po.CO2 Ml'! 30 34 e 
Vd/lJt •, 27 29 0 ,. 
VA ll'M 8 29 0 
P<102 AM 91 85 0 
Sa02 ~ .. q.., - , q.., - , 0 
PA02 l"lM 108 111 0 
A-aD02 Ml"I 17 26 e 
QS..t'QT % 1 2 0 
QT l/M 2.5 8.7 0.0 
STR. lJOL Ml 28 51 0 
PH 7.42 7.39 0.00 
LACTATE l'lf'I/ l 0.0 0.0 0.0 
PREDICTED VHLUES: 




FEtJ1: 2380 ril 
FEVl: 2450 Al 








. . . 
. . . . . . 
50 L....-1-2--~3-4~~5~6~~7~-9~~9~1M0~.':12 
w.LOAD<x100)kpMl~in 
M.LOAO HEART VEHT. RESP. 
k,:>fi.•'l'I RHTE L,.trt RATE 
0 92 11 15 
100 110 16 20 
200 129 22 ~,. -t> 
300 135 26 29 
400 150 31 29 
500 160 35 . 30 
680 170 43 32 
700 179 45 · 32 
800 185 56 36 
900 190 6? 44 
W.LOftO kp,Vft REST 400 550 
HEART RATE 92 170 180 
VI . '"" 11 33 47 tJt "' 702 1207 903 RESP.RATE 15 27 52 U02 "l /ft 256 1042 1435 
IJ02 ftl/k9/11 S.7 23.2 31.9 UC02 "' "" 241 946 1466 R 0.94 0.91 1.02 
PEC02 · '"' 20 25 27 PETC02 "" 37 32 32 PVC02 "" 52 . 67 75 
.. .. ·-.. . 
FtJC: 2700 Pll 





Ra.tio: 88 7. 
Tiftf!: 5 Pli n 
88 · · · · · · · · · · · · · · · · · · · · · · · · 
· - · 
Vt Sa.02 PetC02 BP BP 
fl 1 % l'IMH9 Syst. Dia.s. 
702 90 37 110 70 
785 90 37 
844 90 '35 120 70 
913 90 35 
1070 89 35 140 70 
1152 90 35 
1331 89 34 160 80 
1411 88 35 
1566 88 32 
1527 89 30 
' 
-
W.LOAO kpp11/'H REST 400 550 
Pa.CO2 RM 39 32 35 
IJdl'V t % 28 10 7 
tJA l/f'l 8 29 44 
P.i02 "'"' 90 87 95 Sa.02 % 97 96 97 PA02 f'I" 107 113 114 A-a.D02 I'll'! 17 25 19 
QSl'QT % 3 2 1 QT l /1'1 4.4 6.5 9.2 STR.tJOL Rl 48 38 51 
PH 7.39 7.35 7.35 LACTATE rirvl 0.0 0.0 0.0 
-
Patient 4 




FEU 1: 3080 M 1 
FEUl: 3330 Ml 









1 2 3 4 5 6 7 8 9 10 12 
W.LOAD(x100)kpM/Min 
W.LOAD HEART lJENT. RESP. 
kpr>VM RATE L..-1'>1 RATE 
0 75 16 22 
100 95 18 21 
200 q- 25 26 -0 
300 105 29 ?"" ... r 
400 114 32 ·:>"" ... r 
500 124 38 28 
600 138 48 29 
700 150 51 29 
800 168 65 35 
900 189 84 41 
1000 195 1 ·:>·;> 57 --
.. 
W. LOAD kpf'l-"N REST 400 600 
HEART RATE 75 140 156 
IJ I 1.-'N 16 45 55 
lJt 1'11 "'7 •;>? r ....... 1437 1783 
RESP.RATE 22 31 31 
lJ02 foll /M 330 1309 1665 
U02 l'J l /kg .,'f'l 5.3 21. 1 ?- 0 ._t) • V 
VC02 1'11 .•'fol 324 1106 1441 
R 0.98 0.84 0.87 
PEC02 r·rn 18 22 23 
PETC02 MM 33 ?.., ... r ?O .... v 
P~JC02 Mf'l 50 c--. 57 ..J t 
Fl.JC: 4 760 r1 l 















~ 1 2 3 4 5 6 7 S 9 10 1~ 
W.LOADCx100)kpM/Min 
Vt Sa02 PetC02 BP BP 
Ml •, .... r·mHg S~st. Dia.s • 
"'7?? 96 33 110 50 r .... 
841 98 33 
970 G"" 33 120 60 - r 
1061 97 33 
1187 97 33 150 60 
1343 q"'7 33 - r 
1648 98 32 ' 
1754 98 31 
i
I 
1 o-- 98 30 170 vbb 69 
2945 99 23 I 
2145 99 18 
-·· 
W.LOAD kprVr·l REST 400 689 
PaC02 f'lM 34 29 
·:>-, .. r 
~Jd,l.J t •, 28 15 0 .... .., 
lJA 1 .•'r,J 11 38 51 
Pa02 r-11'1 107 1 10 84 
Sa02 •, qo 98 q
-..• -V - t> 
PA02 MM 115 117 120 
A-aD02 1'1 fol 0 
.., 36 .., r 
QS...-QT % 1 0 2 
QT 1 /fol 4.6 0 i= V • .J 10. 2 
STR.UOL £'11 61 61 
-c-
b.J 
PH 7.44 7.33 7.36 








FEU1: 2749 "1 
FEVl: 2:590 ftl 
.............. ·.· . . 
188 
160 




. . . 
:58 L-,1._...2~3~4~5~6~7~8~9~18=--~2 
w.LOAO(x100)kpPl/ftin 
M.LOAD HEART VEHT. RESP. kp .. .l'ft RATE L/,. RATE 
e . 90 13 24 
100 120 14 19 
200 · 128 22 23 
308 137 28 29 
400 144 31 30 
500 152 33 31 
600 178 40 30 
700 180 51 38 . 
·-- -
-··· -
W. LOAD kptV" REST 400 0 
HEART RATE 90 160 0 VI }/ .. 13 46 0 Vt ftl 536 1049 0 RESP.RATE 24 44 0 
V02 .. 1 / .. 290 1296 0 
V02 flll ."kg/ .. 6.4 28.8 0.0 VC02 "1 h• 226 1327 0 
R 0.78 1.02 0.00 PEC02 .... 15 25 0 PETC02 ..... 39 29 0 
PVC02 ..... 49 62 0 
FVC: 3229 ftl Ratio: 85 ~ 





















81..-,,1_2_3_4..__.5~6--',:7,-.8~9.,,._...1.,,,..Q ..... 1.,..,,.2 
W.LOAO<x100)kpP1/"in 
Sa.02 P«tC02 BP BP 
% ftPIHg Syst. Dio.s. 
96 39 120 80 
96 38 
97 37 140 90 
97 38 
96 35 130 100 
96 38 
96 32 130 100 
96 29 
M.LOAD kp,r/PI REST 400 0 
Pa.CO2 .. Pl 37 3S e 
Vd/Vt ~ 31 1S e 
VA }/f'! 9 39 e 
Pa.02 .... 97 99 e : 
SC102 ~ 98 98 e l 





FEUl: 2699 111 
FEUl: 28:SQ ftl 







.. · .. · .. 
. ·· 
.. .. 
. ·· .... -·· 
.·· .• .. ·· .. 
W.LOttO HEART VEHT. 
kpft/ft RATE L/f'l 
e 75 11 
100 103 15 
200 110 26 
J.QQ 122 27 . 490 130 34 
=580 · 142 35 
600 150 42 
790 179 ~2 
W.LOAD kpPVft REST 400 
HEART RATE 75 143 VI 1 /pt 9 43 
Vt "' 556 1114 RESP.RATE 17 39 V02 i't 1 /ft 259 1369 
U02 "l/kg/11 4.3 22.8 vco~ .. 1 .,,., 187 1239 
R 0.72 0.91 
PEC02 '"' 17 25 PETC02 ptH 32 29 
PUC02 f't ... 46 62 
.. .. · 























FUC: 3489 ftl R~tio: 79 ~ 


















1 4 7 9 10 12 
M.LOAO<x180)kpM~"in 
S402 Pt:tC02 BP BP 
X r1r1Hs, S~st. l)ia.s. 
95 32 130 98 
96 29 
96 29 160 108 
97 32 
96 32 179 98 
98 31 
95 33 179 98 
96 31 
W.LOAD kp,,./Pt REST 400 0 
PaC02 tH1 36 32 0 Vd/Vt ~ 26 9 0 VA 1 .,,,. 7 40 0 Po.02 .... 90 101 0 So.02 % 97 98 0 PA02 PU1 103 115 0 A-<1D02 Ml'1 13 15 0 QS/QT % ? 1 0 -QT 1 /1' 4.3 9.5 0.0 STR.VOL Pt 1 57 67 0 








FEV1: 3910 Ml 









.. .. .. 
.. ,/··· .. .. 
.. •·••·· .. .. ·· .. · 
FVC: 4780 f'll Ro. tio: 81 % 
FVC: 4940 Ml · Titte: 5 Min 
150 







50 0 2 4 6 8 10 1214 1618 20 22 24 
W.LOAD<x100)kpM/Min 
4 6 8 1012141618202224 
W.LOAD<x100)kpM/Min 
. .. 
M.LOAD HEART lJEHT. RESP. Ut Sa02 PetC02 BP BP 
kp"/" RATE L/N RATE r, 1 ~ MMH9 S~st. Dias. 
0 93 19 25 767 97 26 
100 96 31 22 1426 98 22 110 70 
200 100 45 30 1510 97 21 
300 110 52 35 1497 97 23 110 70 
400 110 47 32 1460 98 24 
500 112 37 29 1277 97 28 125 70 
· 680 120 51 · 31 1650 97 27 
700 125 46 30 1523 97 31 150 80 
800 135 61 35 1751 97 30 
· 900 145 63 34 1851 97 30 160 80 
1000 160 84 45 ,_1873 97 31 
· 1100 170 90 48 1884 97 26 
- - -
W.LOAD kpr1/r, REST 700 0 W. LOAD kpr'l/M REST 700 e 
HEART RATE 94 140 0 UI }/ .. 22 56 0 
Vt Pl 1 841 2013 0 
RESP.RATE 26 28 0 
IJ02 .. ,/ .. 284 1671 0 
IJ02 Pll/kg/fl 4.6 27.0 0.0 
UC02 .. 1 /f'I 345 1798 0 
R 1.21 1.08 0.00 
PEC02 .... 14 27 0 
PETC02 .... 21 35 0 
PVC02 .... .37 . ts · 0 
PciC02 f'lf'l 28 32 0 : 
Ud/Vt ~ 33 7 0 I 
VA )/M 15 52 0 
Po.02 f'IN 111 102 0 
So.02 % 98 98 0 
PA02 NM 125 119 0 
A-a.D02 MM 14 17 0 QS/QT ~ 1 1 0 .. QT )/M G-g /1...~ 0.0 
STR.VOL Hl h- 8j 0 
PH . 7.53 7.42 0.00 




PREDICTED UALUES: FEU1: 1810 Ml FVC: 2230 Ml 




FE~J 1 : 1 750 M 1 









. . . . . . . . . . . . . . . . . 
50 1 2 3 4 5 6 7 8 9 10 12 
W.LOAD(x100)kpM/Min 
W. LOAD HEART I..IEHT. RESP. 
kpl'l .·' M RATE L.•'M RATE 
0 8r5 11 23 
Hrn 131:1 18 24 
200 155 29 35 
30B 170 39 41 
-- - · -- . - ·- - - -
-- ·-
i... LOA(> kpn.·· l'l REST 100 I:) 
HEART RATE 86 151:l 0 
~JI 1 ··' I'\ 9 32 e 
l.J t Ml 49? 998 0 
RESP.RttTE 19 32 0 
l.102 M} .-' M 195 72c 0 
~J02 H 1 /k~--·1'1 4.5 16.9 0.0 
VC02 1'11 .,.,., 148 631 0 
R 0.76 0.87 0. 0fl 
PEC0:2 rif'l 14 1? 0 
PETC02 Mli ·:)"" -.J 24 0 
PVC02 Ml-l 0 
FIJC: 2090 Ml Ratio: 83 % 







6 0 .. · · · · · · 
B 1 2 3 4 5 6 7 8 9 10 12 
W.LOAD(x100 )kpM/Min 
-
Ut Sa02 PetC02 BP BP 
ril .. r1MH:2t S~st. [,ia.s. ,. 
490 94 25 120 70 
730 94 ".:)C' -.J 
837 94 22 120 70 I 
951 94 20 
., -
W. LOt=tD kpv1,r1 REST idl:l fl 
·-
P11C02 MM 28 7 .. ;, .,_ ~ 
Vd/~J t ~= 20 -i ·::> ..,_ 8 
IJA I / 1'1 , 22 i1 f 
P.:i.02 l'lf'l 91 -,-, 8 .. ( 
S.:i.02 ~ .. : 97 '.:15 8 
PA02 MM 114 113 t) 
A-.i [J(,2 f'lf•l 23 7-. ·-' ( t'.' 
QS .··GIT ~; 1 
-, 
C: f 
QT 1..-r-1 S·1I 11 ·30 1:1. a 
STR. ~JOL 1'1 .1 U, +.r cl 
PH 7.43 7.39 l:l. 88 










FEV1: 4200 Ml 









... .. · . .. . .·• . .• . . · . .• . . . . 
• . . . 
• . . . . . . . 
• • . . 
• • . 
...... 
FVC: 4850 "1 Ratio: 86 % 
FVC: 5020 "1 TiMe! 5 riin 







50 0 2 4 6 a 10 I2 14 1618 20 22 24 
W.LOAD(x100)kpM/Min 
002--4 6 8 10 1214 1618202224 
W.LOAD<x100)kpM/Min 
W.LOAO HEART VENT •. RESP. Ut Sa02 Pll tC02 BP BP 
kp,v" RATE L/1'1 RATE M 1 ~ ririH9 S~st. Dii1s. 
0 80 16 9 1803 96 22 130 80 
100 89 23 12 1909 97 25 
209 96 27 12 2210 97 25 140 80 
300 96 32 13 2441 97 26 
. 400 100 33 17 1927 98 30 160 Hl0 
500 110 32 15 2131 97 31 
600 125 37 17 2153 96 34 160 110 
700 140 47 . 22 2157 96 33 
800 150 49 23 2128 96 32 190 110 
900 160 56 32 1748 96 30 
1800 170 66 36 ·.1832 96 28 190 120 
· 1100 180 80 41 1942 96 25 
W.LOAD kp,./rt REST 500 0 W. LOAD k,:>l'll'M REST S00 0 
HEART RATE 88 120 0 Pa.CO2 Mf't 26 34 0 
VI l /pt 13 42 0 Vd/Vt % 23 10 0 
Vt .. 1 1670 1767 0 
RESP.RATE 8 24 0 
V02 Pll/" 306 17S8 0 
V02 ftl/k9/P1 5.0 28.6 0.0 
VC02 .. 1 /pt 266 1324 0 
R 0.87 0.75 0.00 
IJA 1 /1"1 10 38 0 
Pa.02 1'1fll 101 
~ 
0 
Sa.02 % 98 0 
PA02 Pll'I 122 0 
A-11D02 PlM 20 0 
QS/QT •, 1 0 ,. 
PEC02 ..... 17 27 0 QT l/M 5.3 12.7 0.0 
PETC02 .. ,.. 22 36 0 STR.VOL N 1 60 106 0 
PUC02 .... 34 57 0 PH ?.54 ?.41 8.00 















FEU1: 2620 Ml 
FEU1: 2670 Ml 
. . . . . . ... 
. . 
. . 
• . . . 
50 1 2 3 4 5 6 7 8 9 10 12 
. W.LOAD(x100)kpM/Min 
----
W.LOAD HEART VENT. RESP. 
KPN ··'M RATE L.•'1'1 RATE 
0 87 11 19 
180 1·:P _, 17 
.,-, _, 
200 150 ?-, 28 ... r 
300 1-,-, 3·1 26 r r 
· 400 185 41 31 
500 190 63 47 
W. LOAD KPl'l-·'l'l REST 300 0 
HEART RATE 87 170 0 
lJI 1 /[11 11 38 0 
Vt 1'11 673 1089 0 
RESP.RATE 17 35 0 
IJ02 I'll /[11 269 923 0 
1,102 Pl 1 /'k~ .-·('1 4.6 15.6 0.0 
lJC02 Ml /M 206 909 0 
R 0.76 0.98 0.00 
PEC02 MM 16 21 0 
PETC02 fllf'l 33 27 0 
PVC02 £'11'1 47 . 55 0 
F~JC: 2840 M 1 







Ra. tio: 92 




1 2 3 4 5 6 7 8 9 10 1~ 
W.LOAD(x100)kpM.l'Min 
.. .. 
lJ t Su02 PetC02 BP BP 
1'11 % 1'1r1Hg Syst. Diu.s . 
565 q-, - r 33 11 El 70 
631 97 29 
q'~ _ bb 97 30 120 70 
1207 q-, - r 30 
1332 97 
.,,_, ... ( 140 70 
1335 96 22 
W. LOAD kpr•Vr·1 REST 300 0 
PaC02 Nfol 33 ·:;,o ... v 0 
lJcVU t •, 30 13 0 ·'• 
VA l /M 8 33 e 
Pa02 MN 95 HM 0 
S1102 .. 98 qo 0 ~. _v 
PA02 l'lf'l 108 129 0 
·A-aD02 1'11'1 13 16 9 
QS.,-QT ~; 1 1 0 
QT 1 /[11 3. 1 7.3 0.9 
STR. l.JOL r·1 l 36 43 0 
PH 7.42 7.34 0.00 






Pre-exercise: FEU1: 4020 Ml 




FUC: 4940 r·1 l 













..... ················ . 
.. ·· Vent. .·· -·· 
100 t (······ 
80 •.. · 
50 0 2 4 6 8 10 12 14 1618 20 22 24 
W.LOAD(x100)kpM/Min 
lol.LOAD HEART VENT. RESP. 
kpfll/N RATE L..-1'1 RATE 
I e 74 10 11 ' i 100 97 22 .12 
290 99 20 13 
300 112 ,., .. ... t) 14 
480 128 29 16 
500 140 37 16 
600 150 44 16 
700 152 49 18 
800 165 51 19 
900 175 63 24 
1000 188 79 29 
i : . 
W. LOAD kpf'l .·'N REST 500 0 
HEART RATE 92 147 0 
VI 1 .•'N 12 49 0 
~Jt 1'11 1231 2141 0 
RESP.RATE 10 23 0 
l.J02 M 1 .•'r•l 3..,., , ... 1518 0 
V02 1'11 .··kg/1'1 3.7 15.2 0.0 
UC02 1'11 / flt - 273 1 .. c;- ., b..J ... 0 
R 0.73 1. 09 0.00 
PEC02 ('11'1 19 29 0 
PETC02 l'lfol 33 33 0 
Pl-1C02 Mfol 44 62 0 
Patient 12 
L/'N 
00 2 4 6 8 1012141618202224 
W.LOAD<x100)kpM.-"Min 
~J t Sa02 PetC02 BP BP 
Ml •, . -. r·mHg Syst. Di us . 
924 98 37 170 qc:-- .J 
1824 99 38 
1516 99 40 200 100 
1846 99 42 
1824 99 41 119 q= - .J 
2292 99 43 
2736 · 99 42 220 190 
2736 99 39 
2676 98 40 220 100 
? ... ,.., 
... t:>._ r 99 34 
2718 98 30 230 100 
·- -- - -- -
W. LOAD kpr·1/N REST 500 0 
PaC02 fllM 33 38 0 
lJd/U t .. 30 18 0 ..• 
lJA 1 /fol 9 41 0 
Pa02 r·1 f'1 90 99 0 
Sa02 .. q.., 97 0 ..• - r 
PA02 r•1 fol 104 112 0 
A-aD02 l'l fol 14 22 0 
QS.-·QT .. 2 2 0 ..• 
QT 1 /fol 5.4 16.6 0.0 
STR. l.JOL f'l 1 59 113 0 
PH 7.42 7.38 0.00 






FEV1: 3490 1"11 
FE~J1: 3600 Ml 
FVC: 4640 I'll 
FVC: 4S80 I'll 
Ratio: 75 ~ 










.. .. · .. . ·· .. ·· 
.... ········ .. 
.... ·· 
.-·· .. · 
Vent. 
L/1"1 
50 0 2 4 6 8 1012141618202224 
W.LOAD(x100)kpM/Min 
W.LOAD HEART t'EHT. RESP. Vt 
kpM.•'M RATE L/M . RATE Ml 
0 65 15 18 853 
100 82 18 18 993 
200 82 23 19 1189 
300 90 29 20 1432 
400 q--_b 34 22 1561 
S00 119 45 25 1787 
600 120 53 28 1S83 
700 12S 60 27 2206 
800 135 70 33 2113 
900 140 86 36 2375 
. .. 
W.LOAD kpPt/1'1 REST 450 0 
HEART RATE 60 125 0 
VI 1 /Pt 12 47 0 
Vt rd 693 1878 0 
RESP.RATE 17 2S 0 
V02 "l/M 233 1240 0 
IJ02 .. 1/kg/r, 3.1 16.3 9.0 
VC02 t1l/P1 260 1470 0 
R 1.11 1.19 0.00 
PEC02 Mf'l 19 27 0 
PETC02 MM 28 33 · 0 






00 2 4 6 8 101214 1618202224 
W.LOAD(x100)kpA/Min 
Sa02 PetC02 BP BP 
% Ml"!Hg Syst. Di as. 
47 23 110 80 
97 28 
9? 29 130 90 
97 32 
97 31 142 80 
97 32 
q-, 
- r 29 150 90 
98 28 
· 98 26 170 80 
98 23 
W.LOAD kpr,/11 REST 450 8 
PaC02 """ 32 31 0 Vd/lJt % 19 5 0 
VA 1 /f1 10 45 . 0 
Pa02 ('trt 101 110 0 
S<102 % 98 98 0 
PA02 Ml'1 120 123 0 
A-ciD02 Ml'1 19 13 0 
QSl'QT % 1 1 0 
QT l/M 3.8 14.5 0.0 
STR.VOL Ml 64 116 0 
PH · 7.45 7.39 0.00 





FEU1: 4590 Ml 






~ , , , 
~. 
/• , . , 
Fl.JC: 5280 r-11 
FUC: 5350 r-11 
150 
140 
Ra.tio: 86 % 










, , , 
50 0 2 4 6 8 1012141618202224 
W.LOAD(x100)kpM/Min 
... - . 
W.LOAD HEART ~JENT. RESP. Vt 
kprVl'l RATE Ll'N RATE Ml 
g 82 17 18 ' 922 
190 87 28 18 1537 
290 90 32 
.,., .__ 1462 
300 97 40 18 2240 
400 102 50 ?? ...... 
.,.,-,-, 
.__ r t 
500 106 55 21 2641 
600 112 6? 24 2593 
700 119 I 73 23 3168 
800 · 124 88 29 3023 
990 134 109 36 3027 
1000 142 123 41 · 3012 
J.I. LOAD kPl'l--'1'1 REST 500 0 
HEART RATE 78 113 0 
VI 1 /1'1 14 -,.::> r ,._ 0 
~Jt Ml 1109 2683 0 
RESP.RATE 13 
.,., 
,._ r 0 
~102 1"11 /1'1 331 1560 0 
l.J02 Ml /kg.•'l'l 3.6 17. 1 0.0 
l.JC02 N l .•' l'l 265 1458 0 
R 0.80 0.93 0.00 
PEC02 NM 16 17 0 
PETC02 fol 1'1 25 22 0 
P~JC02 NM 35 43 0 
Patient 14 
0,,. ,.. .... 6 8 10 1214 1618202224 
W.LOAD(x100)kpM/Min 
I 
Sa.0'2 PetC02 BP BP .. r·mHg S~:::: t. td 115, '• 
92 25 110 8Ei 
92 25 
91 24 120 89 
90 25 
89 24 130 8Ei ! 
88 24 i I 
88 23 140 8Ei 
88 24 
88 22 170 90 
88 21 
88 18 190 100 
W. LOAD kpr•1.··r·1 REST 500 0 
PaC02 folfol 30 26 0 
l)d/~J t. .. .•, 33 ?-, _, 0 
UA 1 /fol 10 53 0 
Pa02 f'lfol 73 €1 0 
Sa02 .. qc 92 0 r. - .,J 
PA02 l'lf'l 113 121 0 
A-11D02 f'lfol 40 60 0 
QS.··QT .. 11 9 0 .... 
QT l /N 9.7 16.4 0. 0 . 
STR. l)OL r-1 l 1 ·)C" ,._._J 145 0 
PH 7.42 7.40 0.00 




FEV1: 3100 I'll 









..............• ·.• . . 
. . 
.· 
. . . 
. . 
50 1 2 3 4 5 6 7 8 9 10 12 
W.LOAD(xi00)kpM/Min 
- ·-
Iii.LOAD HEART VENT. "RESP, 
kp,.. ...... RATE L/N RATE 
0 81 10 · 15 
100 .105 19 21 
200 119 26 21 
300 129 35 26 
. 400 158 51 33 
500 155 54 30 
- 600 169 71 39 
W. LOAD kpM.•'M REST 300 0 
HEART RATE 81 129 0 
VI 1 t>' M 9 34 0 
Vt Ml 764 1482 0 
RESP.RATE 12 23 0 
V02 N 1.•'1"1 235 1038 0 
V02 1'11 /kg/rt 3.9 17.3 0.0 
l)C02 M 1 .·'1'1 174 829 0 
R e.74 0.80 0.00 
PEC02 NM 16 21 0 
PETC02 MM 32 29 0 
PVC02 NM 42 51 0 
FVC: 3780 I'll Ratio: 82 % 









e• I I I ft t I I t I t 6 t 
1 2 3 4 5 6 7 8 · 9 10 12 
M.LOAD<x100)kpP1/Ain 
- . . - - . -
Ut Sa.02 PetC02 BP BP 
.. 1 ~ fl!MH9 S!::lst. Dias. 
676 97 32 130 90 
909 97 30 
1227 97 33 150 100 
1328 97 30 
1537 97 29 170 110 
1803 97 27 
1809 97 23 
W.LOAD kpf>l/M REST . 300 0 
PaC02 ftM 35 31 0 
Vd/Vt ~ 34 21 0 
VA 1 /J"I 6 27 0 
Pa02 MM 93 98 0 
Sa02 % 97 98 0 
PA02 111111 105 113 0 
A-aD02 MIil 12 15 0 
QS...-QT .. 3 1 0 "• 
CH 1 _...M S.5 8.7 0.0 
STR.VOL ,., 1 68 68 0 
PH 7.42 7.41 0.00 







FEVt: 2940 ,.1 









/• , , 
~ , 







FVC: 3630 ,.1 Ratio: 80 ~ 









... ·· .. 
. . 
50 0 2 4 6 8 10 1214 1618 20 22 24 
M.LOAD<x100)kp"/Min 
. 90 2 4 6 8 101214 1618292224 
W.LOAD(x100)kpft/ftin 
. - . . 
W.LOAD HEART UEHT. RESP, Ut Sa02 PetC02 BP BP kp .. ,. .. RATE L,.,. RATE Pl 1 . % PlftHg S~st. Dias. 
8. 90 17 2? 6.11 95 31 120 70 1aa . 100 .. 24 32 754 95 33 208 105 23 28 824 94 33 140 80 300 119 29 28 103? 94 34 · 400 138 3~ 33 1056 94 34 140 80 ,ae 144 38 33 1159 94 34 
· 688 150 :51 34 1488 94 32 140 80 
.. 
-
W.LOAD kpft/ft REST 300 0 W.LOAD kpf1/P1 REST 300 . 0 
HEART RATE 90 124 0 PciC02 .... 36 35 - 0 -
VI 1,.. .. 17 31 0 IJd/lJt % 31 . 20 0 
Ut fll 611 1045 0 UA l/N 11 25 0 
RESP.RATE 27 30 0 Pa.02 .... 90 91 0 . 
U02 "' "" 353 944 0 Sci02 ~ 9? 97 0 : V02 ftl/k9/P1 . 5.6 15.0 0.0 PA02 "" 108 110 0 VC02 .. 1,.,. 304 835 0 A-aD02 "'" 18 18 e R 0.86 0.88 0.00 QS/QT .% 3 2 0 
PEC02 .... 16 23 0 QT , .,.,. 6.5 11. 3 0.0 
PETC02 .... 31 32 0 STR.VOL .. 1 -,? ' .... 91 0 PUC02 .... 46 52 0 PH 7.41 7.37 0.00 
LACTATE ftPt/1 0.0 0.0 0.0 







FEV1: 3250 ,.1 
FEIJ1: 3350 Ml 








.. .-·· .. 
.. · . .. . .. . . . . . 
50 1 2 3 4 5 6 7 8 9 10 12 
W.LOAO(x100)kpM/"in 
... 
M.LOAO HEART VEHT. RESP. 
kpf'll'l't RATE L/t1 RATE 
0 98 11 21 
· 100 112 16 14 
208 122 25 26 
300 124 31 29 
· 400 140 37 24 
500 142 42 31 
600 145 44 33 
' 
W. LOAD kpM .·'M REST 250 0 
HEART RATE 98 1 ·::>-, .... ( 0 
IJ I l /N 11 34 0 
IJt Ml 529 1183 0 
RESP.RATE 21 29 0 
l.J02 Nl /N 235 1025 0 
~J02 r,11.•'k~ -·'M 4.3 18.8 0.0 
lJC02 Ml / ['1 178 994 0 
R · 0.76 0.97 0.00 
PEC02 f>H'l 14 ';>C' 0 .... ..J 
PETC02 r·m 29 31 0 
P~lC02 fll'l 43 53 0 
' 
FlJC: 3880 .. 1 Ra.tio: 83 
.. ..• 



















0 1 2 3 4 5 6 7 s 9 10 12 
W.LOADCx100)kpM/Min 
. -
So.02 PetC02 BP BP 
~ Mf"IH9 Syst. Dias. 
94 29 110 . 60 . 
93 36 
93 36 130 70 
93 37 
93 35 150 70 
93 34 
93 33 
W.LOAD kpf'l/f'l REST ·250 0 
PaC02 f,1£,1 37 35 :1 lJd.-'\J t •, 34 16 /. 
VA 1 ,/r,] 
-, 29 ( 0 1 
Pu02 Mr•l .::p 101 0 1 - .., 
Su02 .. q.., qo 0 ... - ( - ..., 
PA02 ('lf'l 104 114 0 1 
.A-aD02 r·m 11 13 e ! 
QS.·'{H 
.. 2 1 0 : "• 
QT l /£'1 6.3 12.6 0. 0 · 
STR.lJOL f'l 1 64 100 0 
PH 7.43 7.41 0.00 
LACTATE r,11'1 .·' 1 0.0 0.0 0.0 









FEU1: 4459 Pll 




··································:-_,,. . ., . ...... 
. .,. . 
,/ : ,· . ,.,. 
FVC: 5150 I'll 





r ' 'f., 
Rci tio: 86 · % :~ 
TiP,e: 5 Plin: 






.. ,· Vent. 80 












300 . 88 







UI 1 ...... 
Ut "1 
RESP.RATE 
U02 .. 1,. .. 
U02 ftl/kg/ .. 
UC02 .. 1 / .. 
R 
PEC02 "" PETC02 ....
















































































. · ~.,~ 
.. -... ~: 
80 2 4 6 a 1 e 12 14 16 1 a 20 
M.LOAD<x100)kpft/Plin 
· "~~-
SCl.02 PctC02 BP· BP ::•~1-
% .. MH9 S~st • Dia.s '-~' ...... ' 
94 33 110 70 
. -~'.: 
94 34 
94 34 130 80 
94 35 
94 35 130 80 
95 36 140 80 
96 36 
96 34 150 90 
96 35 
-·-· -- - .. 
M.LOAD kpM/rt REST 350 E 
Pa.CO2 "M 33 3S f 
IJd/Ut ~ 30 24 E 
IJA 1 h• 12 32 E 
Pa.02 . .,.. 98 88 E 
Sa.02 % 98 97 E 
PA02 ..... 106 113 E 
A-a.D02 "'"' 8 26 E QS/QT % 1 2 E 
QT 1 / .. 6.0 10.3 0. E 
STR.IJOL Pt 1 83 105 . E 
PH 7.45 7.39 0.' 0f 




FEV1: 2170 "1 







....................• .. . .. . 
.. ·· .. 
.·· 
.. .. 
.. ··· ... ·· .. 
. . 
100 t .. ·· . . . . . 
• se r • • • 
50 
1 i 2 j 4 ~ 6 7 8 § i 0 1 12 
M.LOAD<x100)kp~/Ptin 
W.LOAD HEART VEHT. RESP. 
k J) "' I' fll RATE L/r, RATE 
0 110 9 14 
·. 100 128 19 25 
200 148 27 .31 
300 150 30 · 34 
. 400 150 34 35 
L..--
W.LOAD kp111/"' REST 150 0 
HEART RATE 110 140 0 
VI 1 /l'J 10 29 0 
IJt .. 1 688 983 0 
RESP.RATE 14 32 0 
V02 .. 1/ .. 224 1032 0 
V02 .. 1/kg/ .. 3.2 14.S 0.0 
VC02 .. 1 ,,. .. 180 726 0 
R 0.80 0.70 0.00 
PEC02 Pl .. 16 22 0 
PETC02 PIM 35 31 0 
PVC02 PIPI 45 52 0 
Patient 19 
FVC: 2530 ,.1 Ratio: 85 % 


















e• I I I I I I I I I C O J 
1 2 3 4 5 6 7 8 9 10 1 
M.LOAD(x100)kp"l"i~ 
Sa02 P«tC02 BP BP 
% PIPtHg S~st. Dias. 
94 35 · 1~9 90 
94 34 
93 31 170 100 
93 32 
93 30 
W.LOAD kp,../rt REST 150 e 
PciC02 PIPI 38 40 0 
Vd/Vt - % 35 28 0 
VA 1 /" 6 21 0 
Pci02 ('11 .. 83 81 0 
S<102 ~ 96 96 0 
PA02 "'"' 103 95 0 1 A-a.D02 ..... 21 14 0 1 
QS/QT ' % 6 3 · 0 I 
QT 1 /rt 4.9 13.5 0.0 ! 
STR.UOL .. 1 45 96 0 i 
PH 7.40 7.39 I 0.00 I 






FEV1: 2960 "1 












. . . . 
. . 
50 I i 2 3 4 5 6 7 8 9 1 i 0 1 12 
M.LOAD(x100)kp~/11in 
. . .. .. - . . - . . . . 
M.LOAD HEART UEHT. · RESP. 
kpft/ft RATE L/" RATE 
e 76 19 21 
. 100 78 21 2~ 
200 80 27 24 
300 82 32 26 
· 400 85 33 25 
580 115 35 25 
· 600 130 38 26 
700 136 - 43 29 
800 150 47 28 
· 900 160 55 29 
- --- --
--- - - --- -- . 
W. LOAD kprt/ft REST 450 0 
HEART RATE 56 144 0 
VI l/11 1S 47 0 
Vt . .. 1 688 1583 0 
RESP.RATE 22 30 0 
V02 ,.1 ,,,. 363 1560 0 
U02 Pll/kg/,. 5.7 24.6 0.0 
VC02 .. 1,, .. 279 1102 0 
R 0.7? 0.71 0.00 
PEC02 ""' 16 20 0 PETC02 . ttPI 29 28 0 
PUC02 ..... 45 62 0 
FVC: 3670 Ml Ratio: 80 ~ 






















0 1 2 3 .4 s 6 1 a 9 1e 1, 
W.LOAD(x100)kpM/Min 
Sa.02 Pe tC02 BP BP 
.% Ml"IHg S~st. Dias. 
94 30 120 ee 
97 30 
96 32 130 85 
97 32 
97 31 130 89 
97 31 
95 32 130 80 
94 39 
94 38 140 70 
95 31 
W.LOAD kpN/1'1 REST 450 0 
Po.CO2 ~l'I 39 40 0 
IJd/l,l_t % 37 40 0 
UA 1 /" 9 29 0 
Po.02 ,..,.. 105 80 0 
So.02 % 98 94 0 
PA02 l'IM 100 96 0 
A-o.002 PU1 0 16 0 
QS/QT % 0 4 0 
QT 1 /rt 10.4 12.3 0.0 
STR.VOL I'll 185 85 0 
PH 7.41 -, ,,-t • ... b 0.00 




Pre-exercise: FE,J 1: 3190 "'1 
Lowest post-: FEVl: 3120 Ml 
200 r 














1 2 3 4 5 6 7 8 9 10 
w.LOAD(x100)kpM/Min 
W.LOAO HEART \.JENT. RESP. 
kpM .·' M RATE L.-'M RATE 
e 86 9 13 
h38 100 14 25 
280 108 21 19 
300 133 26 22 
40e 150 37 ?.., _, 
500 170 51 34 















-·. ---· - ------
W. LOAD ksm.··r1 REST 
HEART RATE 86 
VI l .r'M 9 
Vt Ml 707 
RESP.RATE 13 
V02 M 1 /N 235 
V02 M 1 /kg/rl 3.7 
VC02 Ml /M 165 
R e.70 
PEC02 l'lr-1 16 
PETC02 Nl'l 31 
PVC02 Ml'l . 44 


















1 FEB 1981 
4040 p,1 R11tiu: 78 
.. ..• 









. . . . . . . . . . . . . . . . . . . . . . . 




























MM .. ,-. 
PH'l 





























':• C _...., 
28 
76 
q -
- t:; 
114 
38 
4 
... ? 
r ' -
'70 e 
7.46 
e.0 
e 
e 
0 
0 
8 
B 
e 
8 
8 
9,13 
9 
e.ee 
e.e 
